DEAR DOCTOR, COULD YOUR PATIENT’S UNEXPLAINED GASTROINTESTINAL SYMPTOMS BE CAUSED BY MAST CELL ACTIVATION SYNDROME?

Ruth Slater*, Helen Bowes. Mast Cell Action, UK

10.1136/gutjnl-2020-bsgcampus.419

Introduction Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells are inappropriately activated leading to inflammatory and allergic-type symptoms to everyday triggers such as food, chemicals, stress and more. Destabilisation of the mast cell has a direct impact on the gastrointestinal (GI) tract and patients with the symptoms of MCAS are often referred to a gastroenterologist for investigation.

Methods To assess how MCAS impacts the GI system, the charity Mast Cell Action undertook a UK-wide online survey of adults and children (via their carers) with a confirmed or suspected diagnosis of MCAS. The survey evaluated symptoms most frequently experienced, tests and investigations commonly undertaken, and medical management strategies.

Results The survey was completed by 112 adults and on behalf of 30 children. A diagnosis of MCAS was confirmed in 68/112 (61%) of adults and 17/30 (57%) of children. The three most common GI symptoms were bloating (n=100 [89%]), pain (n=96 [86%]) and diarrhoea (n=90 [80%]) in adults, and pain (n=26 [87%]), GERD (n=24 [80%]) and constipation (n=22 [73%]) in children. Adults most frequently underwent investigation for coeliac disease (n=73 [65%]) and IBS (n=68 [61%]) whereas children underwent investigation for coeliac disease (n=16 [53%]), GERD (n=10 [33%]) and H. Pylori (n=8 [27%]). The surveyed patients had undergone a wide range of tests and investigations, with 72 adults (64%) and 14 children (47%) undergoing endoscopy and 59 adults (53%) and 8 children (27%) undergoing colonoscopy. In addition to MCAS, the most common diagnoses were IBS (n=48 [43%] and n=4 [13%], respectively), GERD (n=23 [21%] and n=7 [23%]) and coeliac disease (n=10 [9%] and n=2 [7%], respectively). Medical management strategies most frequently involve sodium cromoglicate, ranitidine, and PPIs. Diet modification was reported by 76 adults and 17 children; 32 adults and 13 children currently have a gastroenterologist leading their care.

Conclusions This patient-reported survey indicates that MCAS patients experiencing GI symptoms are frequently investigated for a range of conditions. MCAS is notoriously difficult to diagnose, requiring a combination of multisystem symptoms, biological mediator test results and response to treatment. Although most recognised for its acute allergic symptoms (particularly anaphylaxis), the chronic symptoms of MCAS can be severely debilitating and significantly impact patient lives. GI symptoms are one of the most frequent chronic symptoms of MCAS due to the high presence of mast cells in the gut.2 This survey confirms the range of GI symptoms suffered by people with MCAS and highlights the need to access the right tests and clinical review in order to achieve a diagnosis.

REFERENCES

P346 ABDOMINAL FUNCTIONAL ELECTRICAL STIMULATION A NOVEL TREATMENT FOR NEUROGENIC BOWEL MANAGEMENT IN MULTIPLE SCLEROSIS

1Christine Singleton, 1Carla Peace, 2Samir Vyas, 3Tamsyn Street*. 1Birmingham Community NHS Healthcare Foundation Trust, Birmingham, UK; 2New Hall Hospital, Ramsay Healthcare, Salisbury, UK; 3Salisbury NHS Foundation Trust, Salisbury, UK; 4Bournemouth University, Bournemouth, UK

10.1136/gutjnl-2020-bsgcampus.420

Introduction Neurogenic bowel dysfunction for people with Multiple Sclerosis (PwMS) is a debilitating condition leading to a lower quality of life. Initial studies suggest abdominal functional electrical stimulation (ABFES) could be an effective (6 weeks) short term bowel management treatment, however, long-term benefits remain unexplored (Street, Peace, Padfield, Singleton, 2019, Neurodegenerative Disease Management, 9:83–39). Low compliance with standard care treatments for bowel management indicates a need to explore alternative treatments. The current study sought to explore the acceptability and effectiveness of using ABFES over a 24-week period and provide data for a future randomised controlled trial.

Methods Thirty-four PwMS with constipation (ROME IV criteria) participated in the study. A two-channel neuromuscular stimulator was used to elicit a visible contraction of the anterior abdominal wall muscles (stimulation parameters 40 Hz, 300 μ sec pulse width and 40–50 mA). Participants self-administered treatment at home for 30 minutes twice a day for six weeks and titrated for need thereafter. The Patient Assessment of Constipation related Quality of Life (PACQol) questionnaire was completed at baseline, six weeks and six months (PACQol minimum clinical important difference (MCID) = 0.5 points).

Results A non-parametric Friedman test of differences among repeated measures found an overall significant difference in...